Interventions promoting Apitolisib clinical trial informative counselling on effective contraception, motherhood planning, and the prevention of MTCT are greatly needed in the setting of routine care of HIV-infected women. We acknowledge Women for Positive Action (WFPA), a global initiative established in response to the need to address specific concerns of women living and working with HIV. The DIDI Study Group stemmed from the WFPA Italia. Study coordinators: Antonella d’Arminio Monforte (Milan) and Adriana Ammassari (Rome). Study participants: Enza Anzalone (Frosinone), Teresa Bini (Milan), Antonella Castagna (Milan),

Anna Maria Cattalan (Rovigo), Gabriella D’Ettorre (Rome), Fiorella Di Sora (Rome), Daniela Francisci (Perugia), Miriam Gargiulo (Naples), Nicoletta Ladisa (Bari), Giuseppina Liuzzi (Rome), Tiziana Quirino (Busto Arsizio),

Raffaella Rosso (Genova), Maria Paola Trotta (Rome) and Francesca Vichi (Firenze). Experts: Antonella Cingolani (Rome) and Rita Murri (Rome). Statistician and data manager: Paola Cicconi (Milan) EPZ015666 research buy and Paola Pierro (Rome). “
“As access to antiretroviral drugs increases in developing countries, it will become increasingly important to monitor the emergence of resistance and to define the molecular pathways involved to identify optimal therapeutic regimens. We performed genotypic resistance testing on plasma obtained from 101 HIV-infected treatment-naïve Megestrol Acetate individuals from Mali. Genotyping was carried out using the Virco protocols and HXB2 was used as the reference strain. CRF02_AG was the most common subtype, present in 71.3% of our patient population. Other

subtypes included B, C, G, CRF06_CPX, CRF09_CPX, CRF01_AE, A2/CRF16_A2D, A1 and CRF13_CPX. A total of 9.9% [95% confidence interval (CI) 6.9–12.9%] of patients had at least one resistance mutation. The prevalences of mutations conferring resistance to nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) were 5% (95% CI 0.7–9.2%), 6% (95% CI 1.3–10.6%) and 0%, respectively. The most frequent mutations were T215A/Y for NRTIs and K103N/T for NNRTIs. One patient harboured three NRTI resistance mutations and one NNRTI mutation. This is the first reported case of multi-drug-resistant viral transmission in Mali. Polymorphisms at protease codons 10I/V and 33F potentially associated with resistance were observed in 18.8% and 1% of patients, respectively. Several polymorphisms in the C-terminal domain of reverse transcriptase were observed: A371V (in 63.4% of patients), G335D (76.2%), E399D (10.9%) and G333E (1%). Primary resistance was seen in 9.9% of subjects, which is higher than previously reported in Mali.